Welcome to our dedicated page for Tyra Biosciences news (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences stock.
Tyra Biosciences develops clinical-stage precision medicines that target Fibroblast Growth Factor Receptor (FGFR) biology. News about TYRA commonly centers on its SNÅP drug-design platform, oral dabogratinib as an FGFR3-selective inhibitor, and pipeline programs in targeted oncology and genetically defined conditions.
Recurring updates include financial results, scientific conference presentations, clinical-study progress in urologic cancers, achondroplasia, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and governance or leadership changes. Company announcements also cover investor-conference participation and program descriptions for TYRA-430 and TYRA-200.
Tyra Biosciences, Inc. (Nasdaq: TYRA) has priced its upsized initial public offering of 10,800,000 shares at $16.00 per share, aiming to raise gross proceeds of $172.8 million. The shares are set to trade on the Nasdaq Global Select Market starting September 15, 2021, with the offering expected to close on September 17, 2021. A 30-day option has been granted to underwriters for an additional 1,620,000 shares. Tyra specializes in precision oncology and is focused on therapies targeting tumor resistance, particularly through its lead product candidate, TYRA-300, for bladder cancer.